Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CytoDyn's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $-119.38 Mil. CytoDyn's Total Assets for the quarter that ended in Feb. 2024 was $10.27 Mil.
The historical rank and industry rank for CytoDyn's Equity-to-Asset or its related term are showing as below:
CYDY'
s Equity-to-Asset Range Over the Past 10 Years
Min: -16.39 Med: -0.38 Max: 0.77
Current: -11.62
During the past 13 years, the highest Equity to Asset Ratio of CytoDyn was 0.77. The lowest was -16.39. And the median was -0.38.
CYDY's Equity-to-Asset is ranked worse than 97.95% of 1562
companies
in the Biotechnology industry
Industry Median: 0.67
vs CYDY: -11.62
CytoDyn Equity-to-Asset Historical Data
The historical data trend for CytoDyn's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoDyn's Equity-to-Asset
For the Biotechnology subindustry, CytoDyn's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CytoDyn's Equity-to-Asset falls into.
CytoDyn Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CytoDyn's Equity to Asset Ratio for the fiscal year that ended in May. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn (OTCPK:CYDY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CytoDyn Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of CytoDyn's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYDY has been successfully added to your 